Changing the Treatment Paradigm in Cancer and Fibrotic Disease

learn more >

ABOUT US » Our Team

CEO and Chief Scientific Officer:

BLR Bio is led by Dr. Bruce L. Riser. Prior to taking on the position of CEO, Dr. Riser directed Baxter Healthcare's Renal Division efforts in the discovery of renal/cardiovascular therapies, technology identification and assessment, strategy formation, and innovation. While at Baxter and in his current positon, he has maintained an appointment as Adjunct Professor of Physiology and Biophysics at Rosalind Franklin University of Medicine and Science and Professor of Medicine at Chicago Medical School. He holds multiple degrees including Public Health (MS) and Cell Molecular Biology/Virology (PhD) from the University of Michigan School of Public Health, and a post-doctorate degree in Pathology from the University of Michigan Medical School. He also has a decade of leadership experience in the Division of Nephrology at Henry Ford Hospital. Dr. Riser has published more than 60 peer-reviewed original articles and book chapters, holds more than 20 patents in a variety of therapeutic and diagnostic areas and is a recognized leader in the identification of key pathways leading to chronic kidney disease as a complication of diabetes and the role of cytokines/matricellular proteins.

Leadership Team:

The leadership team is composed of industry experts in Commercial, Development/Chemistry, Manufacturing and Control (CMC), Regulatory, Clinical and Safety fields. Each management team member has extensive experience (20-plus years in senior positions) in the pharmaceutical/biotech industry.

Research Team:

The research group at the Renal Fibrosis Laboratory at Rosalind Franklin University of Medicine and Science, (RFUMS) and Chicago Medical School where the company’s technology was developed is composed of experts in the fields of molecular, cell, animal, and human biology. The group has world re-known expertise in protein/peptide chemistry, diagnostics and cytokines and the biology (regulation and function) of the extracellular matrix. They are also among the world’s experts in the biology and handling of the CCN proteins.

Scientific Advisors:

BLR Bio has assembled a team of globally renowned advisors in the fields of Oncology, Kidney Disease, Fibrotic Disease and Diagnostics.

© BLR Bio, L.L.C. | 313 54th Street, Kenosha, WI, USA, 53140 |

Latest News

May 2016
"Dr. Bruce Riser, CEO of BLR Bio, was an invited speaker on Peptide Discovery, Preclinical and Clinical presented at the TIDES Oligonucleotide and Peptide Therapeutics Conference, at Long Beach. See selected pre-interview."

April 2016
"BLR Bio was selected as one of the top 50 emerging biotechnology companies to present at the MedCity INVEST, Health Tech Showcase in Chicago April 10-12."

see news archives »


April 2016
Balanced Regulation of the CCN Family of Matricellular Proteins: A Novel Approach to the Prevention and Treatment of Fibrosis and Cancer.
Journal of Cell Communication and Signaling 9.4 (2015): 327–339.
PMC. Web. 28 Apr. 2016.

more publications »